Trump Executive Order on "Most Favored Nation" Drug Pricing Faces Skepticism

US President Donald Trump's executive order on "Most Favored Nation" (MFN) drug pricing aims to align US drug prices with those paid in other developed countries. The order requires the Department of Health and Human Services (HHS) to set target drug prices within 30 days, with pharmaceutical companies negotiating with HHS to reduce US prices over the next 180 days. If negotiations fail, HHS Secretary Robert F. Kennedy Jr. can propose a rulemaking plan, potentially including international drug importation. The order has sparked criticism from analysts, who point out the lack of clarity on implementation and the potential for litigation and regulatory uncertainty.

Key Takeaways:

• The executive order aims to introduce MFN drug pricing, aligning US drug prices with those paid in other developed countries.
• HHS is directed to set target drug prices within 30 days, with pharmaceutical companies negotiating with HHS to reduce US prices over the next 180 days.
• If negotiations fail, HHS Secretary Robert F. Kennedy Jr. can propose a rulemaking plan, potentially including international drug importation.
• Analysts, including Jefferies, have criticized the order for its lack of clarity on implementation and the potential for litigation and regulatory uncertainty.
• The biotech sector initially reacted positively to the news, with the XBI biotech ETF trading higher.
• Jefferies notes that the order's potential impact may be limited, with the possibility that the president and HHS Secretary Kennedy may not have the power to implement MFN pricing without Congressional approval.
• Two potential pathways for implementation have been outlined: using the Centers for Medicare and Medicaid Innovation (CMMI) to test alternative payment models or integrating international reference pricing into the Inflation Reduction Act negotiations.

Statistics:

• 30 days: The timeframe given to HHS to set target drug prices.
• 180 days: The timeframe given for pharmaceutical companies to negotiate with HHS to reduce US prices.
• 2026: The potential start date for negotiations between HHS and pharmaceutical companies.
• 2028: The potential date for changes under the Inflation Reduction Act framework to take effect.

Sources:

• Jefferies (no specific date or publication information provided)
• Trump Executive Order on "Most Favored Nation" Drug Pricing (no specific date or publication information provided)